
diafyt MedTech develops smart devices and AI software to automate diabetes management, specifically for Type 1 diabetics. Their key product, the diafyt app, utilizes artificial intelligence to calculate insulin doses, significantly reducing the risks of over- and under-dosing. The app is certified as a medical device in Europe and aims to improve the quality of life for diabetics by making insulin management easier and more reliable. With a focus on safety and data security, diafyt is positioned to make a substantial impact in the diabetes care market, helping users live healthier lives while managing their condition.

diafyt MedTech develops smart devices and AI software to automate diabetes management, specifically for Type 1 diabetics. Their key product, the diafyt app, utilizes artificial intelligence to calculate insulin doses, significantly reducing the risks of over- and under-dosing. The app is certified as a medical device in Europe and aims to improve the quality of life for diabetics by making insulin management easier and more reliable. With a focus on safety and data security, diafyt is positioned to make a substantial impact in the diabetes care market, helping users live healthier lives while managing their condition.
What they do: AI-powered insulin dosing app and smart devices for Type 1 diabetes
Medical status: App certified as a medical device in Europe
Headquarters: Leipzig, Sachsen, Germany
Founder: Thomas Wuttke
Reported funding (aggregate): 680,000 USD (last reported date 2021-02-15)
Type 1 diabetes management; insulin dosing
MedTech / Digital Health
680000.00